RxDoctor Payments Data

Timothy Wolfe, MD

Hospitalist · Cincinnati, OHNPI 1437458635

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 43.0% of the total. Reporting peaked in 2022 at $364 and has fallen 75.4% since, to $90 in 2025. Among hospitalist clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$962in general payments, 2019–2025

Across 56 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$413
  • AbbVie$227
  • Novartis$59
  • Boehringer Ingelheim$58
  • Johnson & Johnson$47
  • Boston Scientific$31
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$962 in reported general payments places this provider in the 90th percentile of 813 hospitalist providers in Ohio.

See all hospitalist providers in Ohio

Medicare billing

Part B allowed, 2024
$69,082
Medicare patients
242
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$9,130
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$165
Cefdinir19$95
Metoprolol Succinate12$59
Furosemide22$45
Atorvastatin Calcium13$43
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$43
Prednisone17$35
Amlodipine Besylate11$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$9,13016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 813 hospitalist providers in Ohio.

Other hospitalist in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →